In conclusion, the present study highlights that INU ameliorates NAFLD via modulating gut microbiota and suppressing LPS-TLR4-Mψ-NF-κB-NLRP3 inflammatory pathway in mice, which may potentially serve as a potent supplementary therapeutic agent against NAFLD. Here, TLR4 is linked to metabolic dysfunction-associated steatotic liver disease.